DOCSLIB.ORG

Medicines & Vaccines in Development for Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Medicines & Vaccines in Development for Cancer LWW-OTUS_APR10-09-0301-DrugChart-PNK.qxp 4/24/09 7:07 PM Page 1 Medicines & Vaccines in 1 2009 Development for Cancer • his table is adapted from the latest Pharmaceutical Research lymphomas, 52 for myeloma, 63 for ovarian cancer, 54 for pan- Tand Manufacturers of America survey of cancer-related creatic cancer, 27 for sarcoma, 67 for skin cancer, 203 for vari- medicines and vaccines. Of the 861 medicines in develop- ous solid tumors, 27 for stomach cancer, 51 for cancer-related ment—all in either clinical trials or under FDA review—122 conditions, and 129 for other and unspecified cancers (Some are for lung cancer, 106 for breast cancer, 103 for prostate can- of the products target more than one type of cancer.) cer, 70 for colorectal cancer, 23 for bladder cancer, 61 for brain The chart shows the name of each product, the sponsor, cancer, 13 for cervical cancer, 14 for head and neck cancer, 44 the indication, the development status as of the time of the re- for kidney cancer, 129 for leukemia, 35 for liver cancer, 99 for port at the end of March, and a contact telephone number. oncology-times.com Development Development Product Name Sponsor Indication Status Product Name Sponsor Indication Status Bladder Cancer polyphenon E Polyphenon Pharma superficial bladder Phase II New York, NY cancer (212) 661-0578 Advexin® Introgen Therapeutics (see also brain, breast, Phase I (see also leukemia, contusugene Austin, TX head/neck, lung, (512) 708-9310 prostate) ladenovec ovarian, prostate, stomach) pralatrexate Allos Therapeutics (see also lung, Phase II (PDX) Westminster, CO lymphoma) (303) 426-6262 BC-819 BioCancell Phase II Therapeutics SCH-58500 Schering-Plough (see also head/ Phase I Jerusalem, Israel (p53 gene Kenilworth, NJ neck, liver, lung, (908) 298-4000 belinostat Topo Target USA combination therapy Phase II therapy) cancer-related) Rockaway, NJ (see also colorectal, (973) 895-6900 SCH-721015 Schering-Plough Phase I leukemia, liver, Kenilworth, NJ (908) 298-4000 lung, lymphoma, Tarceva® Genentech neoadjuvant therapy Phase II ovarian) erlotinib South San Francisco, (see also brain, breast, (650) 224-1000 CDX-1307 Celldex Therapeutics (see also breast, Phase I CA colorectal, head/neck, (800) 572-1932 Needham, MA colorectal, ovarian, (781) 433-0771 pancreatic) OSI Pharmaceuticals liver, lung, other) Melville, NY Celebrex® Pfizer (see also prostate) Phase III celecoxib New York, NY (860) 732-5156 Valstar® Indevus Pharmaceuticals application valrubicin Lexington, MA submitted CG0070 Cell Genesys Phase I South San Francisco (650) 266-3000 (781) 861-8444 Novartis (888) 669-6682 VB-4845 Viventia Biotech (see also head/neck) Phase II Pharmaceuticals Mississauga, Canada (905) 361-8686 East Hanover, vinflunine Pierre Fabre (see also breast) Phase II NJ Pharmaceuticals (973) 898-1042 Chemophase™ Halozyme superficial bladder Phase I/II Parsippany, NJ hyaluronidase Therapeutics cancer (858) 794-8889 San Diego, CA Brain Cancer EOquin® Spectrum Phase III apaziquone Pharmaceuticals (949) 788-6700 3F8 mAb United Therapeutics neuroblastoma, Phase II Irvine, CA Silver Spring, MD leptomeningeal cancer (301) 608-9292 Erbitux® Bristol-Myers Squibb (see also colorectal, Phase II (see also other) cetuximab Princeton, NJ head/neck, lung, (212) 546-4000 8H9 mAb United Therapeutics Phase I Eli Lilly prostate, stomach) (800) 545-5979 Silver Spring, MD (301) 608-9292 Indianapolis, IN (212) 645-1405 ® ImClone Systems Advexin Introgen Therapeutics glioblastoma Phase I New York, NY contusugene Austin, TX (see also bladder, (512) 708-9310 Hexvix® GE Healthcare diagnostic imaging of application ladenovec breast, head/neck, lung, hexyl Waukesha, WI bladder cancer submitted ovarian, prostate, aminolevulinate stomach) Iressa® AstraZeneca (see also brain) Phase II AEE788 Novartis glioblastoma multiforme Phase I gefitinib Wilmington, DE (800) 236-9933 Pharmaceuticals (see also solid tumors) (888) 669-6682 larotaxel sanofi-aventis (see also pancreatic) Phase III East Hanover, NJ (XRP9881) Bridgewater, NJ (800) 633-1810 AMG 102 Amgen glioma Phase II Levulan® PD DUSA (see also cervical, Phase I/II Thousand Oaks, CA (see also colorectal, (805) 447-1000 aminolevulinic Pharmaceuticals colorectal, lung, (978) 657-7500 kidney, lung, stomach) acid Wilmington, MAstomach) ANG-1005 AngioChem metastatic brain cancer, Phase I MCC/HA Bioniche Life second-line therapy Phase III Montreal, Canada metastatic (514) 788-7800 Sciences Belleville, (800) 265-5464 glioblastoma Canada Armala™ GlaxoSmithKline glioma Phase II OGX-427 Oncogenex (see also breast, lung, Phase I pazopanib Rsch. Triangle (see also breast, cervical, (888) 825-5249 Pharmaceuticals ovarian, prostate) (425) 686-1500 Park, NC kidney, liver, lung, Bothell, WA ovarian, sarcoma, other) continued on next page LWW-OTUS_APR10-09-0301-DrugChart-PNK.qxp 4/24/09 7:07 PM Page 2 2 Medicines & Vaccines in Development for Cancer (cont.) 2009 Development Development • Product Name Sponsor Indication Status Product Name Sponsor Indication Status Brain Cancer gimatecan Novartis glioma Phase I/II (Orphan Drug) Pharmaceuticals (see also leukemia) (888) 669-6682 Avastin® Genentech glioblastoma application East Hanover, NJ bevacizumab South San Francisco, (see also colorectal, submitted GliAtak™ Advantagene Phase I/II CA head/neck, kidney, (650) 225-1000 gene therapy Boston, MA (617) 916-5445 liver, lung, lymphoma, San Diego, CA (760) 943-8981 multiple myeloma, ovarian, pancreatic, ICT-107 ImmunoCellular glioblastoma Phase I prostate, stomach, (cancer vaccine) Therapeutics (818) 992-2907 Woodland Hills, CA oncology-times.com other) ® metastatic brain Phase II Iressa AstraZeneca glioblastoma Phase II cancer from (650) 225-1000 gefitinib Wilmington, DE (see also bladder) (800) 236-9933 NSCLC Karenitecin® BioNumerik (see also lung, ovarian, Phase II Azedra™ Molecular Insight neuroblastoma in Phase II cositecan Pharmaceuticals skin) completed iodine-labeled Pharmaceuticals children (see also other) (617) 492-5554 San Antonio, TX (210) 614-1701 metaiodobenzyl- Cambridge, MA KRX-0402 Keryx brain cancer, Phase II guanidine Biopharmaceuticals glioblastoma (212) 531-5965 Azixa™ Myriad glioblastoma, metastatic Phase II New York, NY (combination therapy), (MPC-6827) Pharmaceuticals brain cancer (801) 584-3600 glioma (combination Salt Lake City, UT (see also skin) therapy) (see also colorectal, kidney, banoxantrone Transcept glioblastoma Phase I/II multiple myeloma, Pharmaceuticals (510) 215-3500 sarcoma) Pt. Richmond, CA laromustine Vion Pharmaceuticals glioma (combination Phase II berubicin Reata Pharmaceuticals brain metastases, Phase II (VNP 40101M) New Haven, CT therapy) (see also (203) 498-4210 (Orphan Drug) Dallas, TX recurrent primary (972) 865-2200 leukemia) brain cancer Lucanix® NovaRx glioma Phase I glioma Phase I belagen- San Diego, CA (see also lung) (858) 552-8600 (972) 865-2200 pumatucel-L BIBW 2992 Boehringer Ingelheim glioblastoma Phase I/II lucanthone Spectrum glioma (combination Phase I Pharmaceuticals (see also breast, (800) 243-0127 Pharmaceuticals therapy) (949) 788-6700 Ridgefield, CT head/neck, lung) Irvine, CA BMS-844203 Bristol-Myers Squibb glioblastoma Phase II MLN8237 Millennium neuroblastoma Phase I/II (VEGF inhibitor- Princeton, NJ (see also solid tumors) (212) 546-4000 Pharmaceuticals (see also leukemia, (800) 390-5663 adnectin) Cambridge, MA lymphoma, solid BSI-201 BiPar Sciences glioblastoma Phase I/II tumors) Brisbane, CA (see also breast, (650) 635-6050 Neuradiab™ Bradmer glioblastoma Phase III ovarian, other) anti-tenascin Pharmaceuticals (502) 657-6038 CC-8490 Celgene glioblastoma Phase II mAb 81C6-I-131 Louisville, KY Summit, NJ (908) 673-9000 (Orphan Drug) CDX-110 Celldex Therapeutics newly diagnosed Phase II/III OncoGel® Protherics glioblastoma Phase I/II (Orphan Drug) Needham, MA glioblastoma (781) 433-0771 Brentwood, TN (see also pancreatic, (615) 327-1027 Pfizer (see also solid tumors) (860) 732-5156 stomach) New York, NY Oncophage® Antigenics glioma Phase II cilengitide EMD Serono newly diagnosed and Phase II vitespan New York, NY (see also colorectal, (866) 805-8994 (Orphan Drug) Rockland, MA recurrent glioblastoma (800) 283-8088 kidney, pancreatic, (see also lymphoma, skin, stomach) prostate, solid tumors) panobinostat Novartis glioma Phase I/II cintredekin NeoPharm glioblastoma Phase III Pharmaceuticals (see also breast, (888) 669-6682 besudotox Lake Bluff, IL (847) 887-0800 East Hanover, NJ leukemia, lymphoma, Cotara™ Peregrine glioblastoma Phase I prostate) mAb TNT-1 Pharmaceuticals (714) 508-6000 patupilone Novartis (see also breast, Phase II (Orphan Drug) Tustin, CA (EPO906) Pharmaceuticals colorectal, liver, (888) 669-6682 DCVax®-Brain® Northwest glioblastoma Phase II East Hanover, NJ lung, ovarian) brain cancer Biotherapeutics (425) 608-3000 perifosine AEterna Zentaris glioma Phase II vaccine Bothell, WA Montreal, Canada (see also head/neck, (212) 531-5965 (Orphan Drug) Keryx kidney, lymphoma, EMD 273063 EMD Serono neuroblastoma Phase II Biopharmaceuticals multiple myeloma, Rockland, MA (see also skin) (800) 283-8088 New York, NY ovarian, sarcoma) enzastaurin Eli Lilly glioblastoma Phase II PRX-321 Protox Therapeutics glioblastoma Phase II (LY317615) Indianapolis, IN (combination therapy) (800) 545-5979 (Orphan Drug) Vancouver, Canada (see also solid tumors) (604) 688-0199 (see also breast, colorectal, Reolysin® Oncolytics Biotech glioma Phase I/II lymphoma, multiple reovirus Calgary, Canada (see also head/neck, (403) 670-7377 myeloma, ovarian, prostate) lung, sarcoma, skin) G 207 MediGene
Load more

Recommended publications
  • Jefferies 2013 Global Healthcare Conference in London
    Jefferies 2013 Global Healthcare Conference in London At the 2012 Jefferies Global Healthcare Conference, there were well over 200 healthcare companies participating with a combined market cap of $1 trillion and close to 1,300 one-on-one/small group meetings over the two-day event. The 2013 conference is set to follow the same footsteps, featuring public and private leading INVITATION global healthcare companies within the areas of pharmaceuticals, biotech, generics, 20-21 NOVEMBER 2013 medtech and healthcare services from the US, Central and Eastern Europe, Latin The Waldorf Hilton America, India, China, Japan, Egypt, Israel and Russia. London, UK Throughout the two-day event, we will feature concurrent tracks of informative presentations as well as 1x1/small group meetings, and thematic panel discussions. This global gathering of institutional investors, private equity investors, VCs and leading executives will address near- and long-term investment opportunities and discuss the mechanisms driving global healthcare. We hope you can join us for what promises to be a unique and comprehensive view of the industry. Registration is now open. Please email your Jefferies representative if you are interested in attending. For general questions, please email [email protected] or contact your Jefferies representative. © 2013 Jefferies LLC. Member SIPC. AGENDA WEDNESDAY, 20 NOVEMBER 2013 Jefferies 2013 Global Healthcare Conference in London ADELPHI 1 ADELPHI 2 ADELPHI 3 EXECUTIVE BOARDROOM 7:30 AM Breakfast & Registration 8:00 AM Clinigen Group Plc Ion Beam Applications Active Biotech AB Syneron Medical Ltd. Specialty Pharma & Healthcare Services Medical Products Biotechnology Medical Technology Paul Thomas; CTO Olivier Legrain, CEO Tomas Leanderson; President and CEO Hugo Goldman, CFO 8:40 AM Valneva Celltrion, Inc.
    [Show full text]
  • Retirement Strategy Fund 2060 Description Plan 3S DCP & JRA
    Retirement Strategy Fund 2060 June 30, 2020 Note: Numbers may not always add up due to rounding. % Invested For Each Plan Description Plan 3s DCP & JRA ACTIVIA PROPERTIES INC REIT 0.0137% 0.0137% AEON REIT INVESTMENT CORP REIT 0.0195% 0.0195% ALEXANDER + BALDWIN INC REIT 0.0118% 0.0118% ALEXANDRIA REAL ESTATE EQUIT REIT USD.01 0.0585% 0.0585% ALLIANCEBERNSTEIN GOVT STIF SSC FUND 64BA AGIS 587 0.0329% 0.0329% ALLIED PROPERTIES REAL ESTAT REIT 0.0219% 0.0219% AMERICAN CAMPUS COMMUNITIES REIT USD.01 0.0277% 0.0277% AMERICAN HOMES 4 RENT A REIT USD.01 0.0396% 0.0396% AMERICOLD REALTY TRUST REIT USD.01 0.0427% 0.0427% ARMADA HOFFLER PROPERTIES IN REIT USD.01 0.0124% 0.0124% AROUNDTOWN SA COMMON STOCK EUR.01 0.0248% 0.0248% ASSURA PLC REIT GBP.1 0.0319% 0.0319% AUSTRALIAN DOLLAR 0.0061% 0.0061% AZRIELI GROUP LTD COMMON STOCK ILS.1 0.0101% 0.0101% BLUEROCK RESIDENTIAL GROWTH REIT USD.01 0.0102% 0.0102% BOSTON PROPERTIES INC REIT USD.01 0.0580% 0.0580% BRAZILIAN REAL 0.0000% 0.0000% BRIXMOR PROPERTY GROUP INC REIT USD.01 0.0418% 0.0418% CA IMMOBILIEN ANLAGEN AG COMMON STOCK 0.0191% 0.0191% CAMDEN PROPERTY TRUST REIT USD.01 0.0394% 0.0394% CANADIAN DOLLAR 0.0005% 0.0005% CAPITALAND COMMERCIAL TRUST REIT 0.0228% 0.0228% CIFI HOLDINGS GROUP CO LTD COMMON STOCK HKD.1 0.0105% 0.0105% CITY DEVELOPMENTS LTD COMMON STOCK 0.0129% 0.0129% CK ASSET HOLDINGS LTD COMMON STOCK HKD1.0 0.0378% 0.0378% COMFORIA RESIDENTIAL REIT IN REIT 0.0328% 0.0328% COUSINS PROPERTIES INC REIT USD1.0 0.0403% 0.0403% CUBESMART REIT USD.01 0.0359% 0.0359% DAIWA OFFICE INVESTMENT
    [Show full text]
  • Immunotherapy in Various Cancers
    © 2021 JETIR June 2021, Volume 8, Issue 6 www.jetir.org (ISSN-2349-5162) Immunotherapy in various Cancers Nirav Parmar 1st Year MSc Student Department of Biosciences and Bioengineering, IIT- Roorkee India Abstract: Immunotherapy in the metastatic situation has changed the therapeutic landscape for a variety of cancers, including colorectal cancer. Immunotherapy has firmly established itself as a new pillar of cancer treatment in a variety of cancer types, from the metastatic stage to adjuvant and neoadjuvant settings. Immune checkpoint inhibitors have risen to prominence as a treatment option based on a better knowledge of the development of the tumour microenvironment immune cell-cancer cell regulation over time. Immunotherapy has lately appeared as the most potential field of cancer research by increasing effectiveness and reducing side effects, with FDA-approved therapies for more than 10 various tumours and thousands of new clinical studies. Key Words: Immunotherapy, metastasis, immune checkpoint. Introduction: In the late 1800s, William B. Coley, now generally regarded as the founder of immunotherapy, tried to harness the ability of immune system to cure cancer for the first time. Coley began injecting live and attenuated bacteria like Streptococcus pyogenes and Serratia marcescens into over a thousand patients in 1891 in the hopes of causing sepsis and significant immunological and antitumor responses. His bacterium mixture became known as "Coley's toxin" and is the first recorded active cancer immunotherapy treatment [1]. To better understand the processes of new and traditional immunological targets, the relationship between the immune system and tumour cells should be examined. Tumours have developed ways to evade immunological responses.
    [Show full text]
  • Advances and Limitations of Antibody Drug Conjugates for Cancer
    biomedicines Review Advances and Limitations of Antibody Drug Conjugates for Cancer Candice Maria Mckertish and Veysel Kayser * Sydney School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia; [email protected] * Correspondence: [email protected]; Tel.: +61-2-9351-3391 Abstract: The popularity of antibody drug conjugates (ADCs) has increased in recent years, mainly due to their unrivalled efficacy and specificity over chemotherapy agents. The success of the ADC is partly based on the stability and successful cleavage of selective linkers for the delivery of the payload. The current research focuses on overcoming intrinsic shortcomings that impact the successful devel- opment of ADCs. This review summarizes marketed and recently approved ADCs, compares the features of various linker designs and payloads commonly used for ADC conjugation, and outlines cancer specific ADCs that are currently in late-stage clinical trials for the treatment of cancer. In addition, it addresses the issues surrounding drug resistance and strategies to overcome resistance, the impact of a narrow therapeutic index on treatment outcomes, the impact of drug–antibody ratio (DAR) and hydrophobicity on ADC clearance and protein aggregation. Keywords: antibody drug conjugates; drug resistance; linkers; payloads; therapeutic index; target specific; ADC clearance; protein aggregation Citation: Mckertish, C.M.; Kayser, V. Advances and Limitations of Antibody Drug Conjugates for 1. Introduction Cancer. Biomedicines 2021, 9, 872. Conventional cancer therapy often entails a low therapeutic window and non-specificity https://doi.org/10.3390/ of chemotherapeutic agents that consequently affects normal cells with high mitotic rates biomedicines9080872 and provokes an array of adverse effects, and in some cases leads to drug resistance [1].
    [Show full text]
  • Say on Pay Results (As of September 5)
    THIS REPORT CAN BE ACCESSED AT HTTP://WWW.SEMLERBROSSY.COM/SAYONPAY NOTE: THIS WILL BE OUR FINAL SAY ON PAY UPDATE FOR 2012. WE WILL ISSUE A FULL REPORT PROVIDING RESULTS FOR THE ENTIRE 2012 PROXY SEASON IN JANUARY 2013. PLEASE CONTINUE TO VISIT OUR SAY ON PAY BLOG FOR UPDATES. SAY ON PAY RESULTS 2012 RUSSELL 3000 SEPTEMBER 5 2012 SAY ON PAY RESULTS: RUSSELL 3000 SHAREHOLDER VOTING SUMMARY OF FINDINGS 2012 Vote Results (n=2,025) 2 The majority of companies continue to pass Say on Pay in 2012 with substantial shareholder support: — 1,466 companies (72%) passed with over 90% support — 381 companies (19%) passed with between 70% and 90% support — 125 companies (6%) passed with between 50% and 70% support — 53 companies (2.6%) in the Russell 3000 have failed Vote of the Week McKesson received a vote of 62%, a decline of 8% from 2011, amidst criticism from shareholders and 3 their advisors over high relative CEO pay and retirement benefits Vote Results by Industry Health Care companies have received proportionally less support than other industries, while 4 Consumer Staple and Financial companies have received the most support Vote Results and Market Value 5 There does not appear to be a strong correlation between a company’s market value and Say on Pay vote result How Vote Results Changed in 2012 6 Companies below 70% in 2011 have generally received increased vote support in 2012: — 26 of 30 companies that failed in 2011 have passed in 2012 — Companies between 50‐70% in 2011 have improved by an average of 13% in 2012 Vote results for companies
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix
    United States International Trade Commission Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix USITC Publication 4208 December 2010 U.S. International Trade Commission COMMISSIONERS Deanna Tanner Okun, Chairman Irving A. Williamson, Vice Chairman Charlotte R. Lane Daniel R. Pearson Shara L. Aranoff Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix Publication 4208 December 2010 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 15, 2010, set forth at the end of this publication, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the United States International Trade Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement changes to the Pharmaceutical Appendix, effective on January 1, 2011. Table 1 International Nonproprietary Name (INN) products proposed for addition to the Pharmaceutical Appendix to the Harmonized Tariff Schedule INN CAS Number Abagovomab 792921-10-9 Aclidinium Bromide 320345-99-1 Aderbasib 791828-58-5 Adipiplon 840486-93-3 Adoprazine 222551-17-9 Afimoxifene 68392-35-8 Aflibercept 862111-32-8 Agatolimod
    [Show full text]
  • The Pipeline Report 2016 Pipeline 2014 Autoimmune
    THE PIPELINE REPORT 2016 PIPELINE 2014 AUTOIMMUNE PRODUCTS GENERATING BUZZ OTHER KEY PRODUCTS IN THE PIPELINE BIG-TIME Baricitinib Eli Lilly/Incyte Indication: RA (Ph.III) Romosozumab Amgen/UCB Sirukumab Janssen Biotech RA What the clinical trials found: The daily oral demonstrated superiority Osteoporosis (Ph.III) (Ph.III) compared to placebo after 12 weeks based on ACR20 response (Ph. Avatrombopag Astellas Pharma Anifrolumab Medarex/Med­ III RA-BEAM). The agent also proved superior to adalimumab on ITP/thrombocytopenia (Ph.III) Immune Systemic lupus erythema- tosus (Ph.III) key secondary objectives of ACR20 response and improvement in Elobixibat AstraZeneca CIC and DAS28-hsCRP score. A few occasional AEs were reported. IBS-C (Ph.III) Odanacatib Merck Osteoporosis (Ph.III) Credit Suisse Success Probability and inThought Comment: 70%. Lesinurad AstraZeneca Gout (Ph. III) Tildrakizumab Merck Psoriasis The JAK inhibitor appears to have similar efficacy and safety to (Ph.III) Pfizer’s Xeljanz. It was supposed to have a once daily vs. Xeljanz’s Alicaforsen Atlantic Healthcare Pouchitis/ulcerative colitis (Ph.III) Siponimod Novartis MS (Ph.III) twice daily advantage, but Xeljanz’s once daily formulation will likely be approved soon. It’ll be interesting to see if Lilly/Incyte Rituximab biosimilar Boehringer Infliximab biosimilar Pfizer RA Ingelheim RA (Ph.III) (Ph.III) can do something with patient access and price to improve upon Mongersen Celgene/Nogra RHB 104 RedHill Biopharma the poor performance of Xeljanz and expand the JAK inhibitor Pharma Crohn’s disease (Ph.III) Crohn’s disease (Ph.III) market. Expected launch: 2016 (Source: Credit Suisse) Etanercept biosimilar Coherus Sarilumad Regeneron RA (Ph.III) Credit Suisse forecast: $1.09 billion in global annual sales by 2020 Biosciences/Daiichi Sankyo/ Etrolizumab Roche Ulcerative A peek at 159 aspiring agents, with profiles on 17 that could shoot to stardom.
    [Show full text]
  • New Contributions in Undergraduate Research
    PSU McNair Scholars Online Journal Volume 11 Issue 1 Without Borders: Original Contributions Article 6 in Undergraduate Research 2017 Wings Outstretched: New Contributions in Undergraduate Research Follow this and additional works at: https://pdxscholar.library.pdx.edu/mcnair Let us know how access to this document benefits ou.y Recommended Citation (2017) "Wings Outstretched: New Contributions in Undergraduate Research," PSU McNair Scholars Online Journal: Vol. 11: Iss. 1, Article 6. https://doi.org/10.15760/mcnair.2017.01 This open access Full Issue is distributed under the terms of the Creative Commons Attribution-NonCommercial- ShareAlike 4.0 International License (CC BY-NC-SA 4.0). All documents in PDXScholar should meet accessibility standards. If we can make this document more accessible to you, contact our team. Portland State University McNair Research Journal 2017 Without Borders: Original Contributions in Undergraduate Research 2017 Ronald E. McNair Scholars Journal Portland State University 1 About the Program The Portland State University (PSU) Ronald E. McNair Scholars Program at Portland State University works with motivated and talented undergraduates who want to pursue PhDs. It introduces juniors and seniors who are first-generation and low income, and/or members of under-represented groups to academic research and to effective strategies for getting into and graduating from PhD programs. The McNair Scholars Program has academic-year activities and a full-time summer research internship. Scholars take academic and skills-building seminars and workshops during the year, and each scholar works closely with a faculty mentor on original research in the summer. Scholars present their research findings at the McNair Summer Symposium and at other conferences, and are encouraged to publish their papers in the McNair Journal and other scholarly publications.
    [Show full text]
  • Drug Delivery Technology Y
    * DDT Nov-Dec 2007 Working 11/9/07 2:29 PM Page 1 November/December 2007 Vol 7 No 10 IN THIS ISSUE Company Profiles 12 Drug Delivery Technologies 58 Excipients, Polymers, Liposomes & Lipids 78 Contract Pharmaceutical & Biological Development Services 83 Machinery & Laboratory Equipment and Software 96 Technology Showcase 102 The science & business of specialty pharma, biotechnology, and drug delivery www.drugdeliverytech.com * DDT Nov-Dec 2007 Working 11/9/07 2:39 PM Page 2 * DDT Nov-Dec 2007 Working 11/9/07 2:40 PM Page 3 * DDT Nov-Dec 2007 Working 11/9/07 2:40 PM Page 4 November/December 2007 Vol 7 No 10 PUBLISHER/PRESIDENT Ralph Vitaro EXECUTIVE EDITORIAL DIRECTOR Dan Marino, MSc [email protected] CREATIVE DIRECTOR Shalamar Q. Eagel CONTROLLER Debbie Carrillo CONTRIBUTING EDITORS Cindy H. Dubin Debra Bingham Jason McKinnie TECHNICAL OPERATIONS Mark Newland EDITORIAL SUPPORT Nicholas D. Vitaro ADMINISTRATIVE SUPPORT Kathleen Kenny Corporate/Editorial Office 219 Changebridge Road, Montville, NJ 07045 Tel: (973)299-1200 Fax: (973) 299-7937 www.drugdeliverytech.com Advertising Sales Offices East & Midwest Victoria Geis - Account Executive Coming in 2008 Cheryl S. Stratos - Account Executive 103 Oronoco Street, Suite 200 Alexandria, VA 22314 Tel: (703) 212-7735 Drug Delivery Weekly & Fax: (703) 548-3733 E-mail: [email protected] Specialty Pharma News E-mail: [email protected] West Coast Warren De Graff Western Regional Manager 818 5th Avenue, Suite 301 San Rafael, CA 94901 Tel: (415) 721-0644 Fax: (415) 721-0665 E-mail: [email protected] 0 The weekly electronic newsletter from the publishers of Drug 1 International o N Delivery Technology and Specialty Pharma will provide over 12,000 Ralph Vitaro 7 219 Changebridge Road l o subscribers with the latest news of business deals, alliances, and V Montville, NJ 07045 Tel: (973) 299-1200 7 technology breakthroughs from the pharmaceutical, specialty 0 Fax: (973) 299-7937 0 2 pharmaceutical, drug delivery, and biotechnology industries.
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • Functional Genomics Approaches to Elucidate Vulnerabilities of Intrinsic and Acquired Chemotherapy Resistance
    cells Review Functional Genomics Approaches to Elucidate Vulnerabilities of Intrinsic and Acquired Chemotherapy Resistance Ronay Cetin 1,† , Eva Quandt 2,† and Manuel Kaulich 1,3,4,* 1 Institute of Biochemistry II, Goethe University Frankfurt-Medical Faculty, University Hospital, 60590 Frankfurt am Main, Germany; [email protected] 2 Faculty of Medicine and Health Sciences, Universitat Internacional de Catalunya, 08195 Barcelona, Spain; [email protected] 3 Frankfurt Cancer Institute, 60596 Frankfurt am Main, Germany 4 Cardio-Pulmonary Institute, 60590 Frankfurt am Main, Germany * Correspondence: [email protected]; Tel.: +49-(0)-69-6301-5450 † These authors contributed equally to this work. Abstract: Drug resistance is a commonly unavoidable consequence of cancer treatment that results in therapy failure and disease relapse. Intrinsic (pre-existing) or acquired resistance mechanisms can be drug-specific or be applicable to multiple drugs, resulting in multidrug resistance. The presence of drug resistance is, however, tightly coupled to changes in cellular homeostasis, which can lead to resistance-coupled vulnerabilities. Unbiased gene perturbations through RNAi and CRISPR technologies are invaluable tools to establish genotype-to-phenotype relationships at the genome scale. Moreover, their application to cancer cell lines can uncover new vulnerabilities that are associated with resistance mechanisms. Here, we discuss targeted and unbiased RNAi and CRISPR efforts in the discovery of drug resistance mechanisms by focusing on first-in-line chemotherapy and their enforced vulnerabilities, and we present a view forward on which measures should be taken to accelerate their clinical translation. Citation: Cetin, R.; Quandt, E.; Kaulich, M. Functional Genomics Keywords: chemotherapy resistance; cancer and drug vulnerabilities; functional genomics; RNAi Approaches to Elucidate Vulnerabilities of Intrinsic and and CRISPR screens Acquired Chemotherapy Resistance.
    [Show full text]
  • Chronic Lymphocytic Leukemia
    Amsterdam, the Netherlands, June 14 – 17, 2012 Chronic lymphocytic leukemia - Clinical 1 assumed efficacy especially in high-risk situations (early relapse, unfavourable prognostic markers), was used in 202 patients. The overall survival in the CHOP-collective was significantly shorter than in the comparative group (p<0.0001) although median observation time was not significantly differ - 0144 ent. However, this observation might reflect a bias in the selection of high risk patients for this relapse treatment. No influence on survival was INFLUENCE OF DIFFERENT TREATMENT REGIMENS ON SURVIVAL IN observed in patients receiving a mitoxantrone-containing regimen at any PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA - A META-ANALY - time during the treatment course. Summary and Conclusions. This meta- SIS OF THE GERMAN CLL STUDY GROUP (GCLLSG) analysis shows that the advances in the development of strategies for first- S Isfort 1, P Cramer 2, J Bahlo 2, R Busch 3, K Fischer 2, AM Fink 2, V Goede 2, T line therapies result in prolongation of treatment-free and overall survival Elter 2, M Bergmann 4, M Stauch 5, S Stilgenbauer 4, CM Wendtner 6, M Hallek 2, for patients with CLL and need of treatment. Chemoimmunotherapies pro - B Eichhorst 2 long the survival independently of the time point of chemoimmunotherapy 1Department of Medicine IV, University Hospital Aachen, Aachen, Germany administration (for first-line therapy or relapse). 2Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany 3 Institute for Medical Statistic and Epidemiology, Technical University Munich, 0145 Munich, Germany 4 Department III of Internal Medicine, University Hospital Ulm, Ulm, Germany A SINGLE-ARM MULTI-CENTER TRIAL OF BENDAMUSTINE GIVEN 5 Private practice and day time clinic for Hematology and Oncology, Kronach, WITH OFATUMUMAB (BENDOFA) IN PATIENTS WITH REFRACTORY OR Kronach, Germany RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA.
    [Show full text]